Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18 years or older~* Female subjects must be using a form of contraception~* \>1 seizures per month~* EEG confirmation of seizure activity (no non-epileptic seizures)~* Agrees to comply with study procedures, and keep seizure diary~* Agrees not to make any major deviations from current diet (especially fish intake) or medications (type, dosage)~* Agrees to having portions of blood samples stored for assays~* Has given voluntary, written, informed consent to participate in the study~Exclusion Criteria:~* Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial~* Use of significant amounts of fish oil or flax oil (omega-3) supplements within 8 weeks of the study.~* Allergy or sensitivity to fish, fish oil, coconut oil, olive oil, hemp oil, safflower oil, flax seed oil, or soybean oil~* Cognitive impairment (I.Q. below 70) and/or inability to give informed consent.~* Failure to understand English~* Subjects taking regular warfarin or aspirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fish Oil (Type: EXPERIMENTAL): Each capsule contains 625 mg of fish oil (100 mg EPA \& 250 mg DHA). Participants will take 12 capsules per day over 6 months.
- Safflower Oil (Type: PLACEBO_COMPARATOR): Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).